“The objective of the fund is to increase UK health resilience by strengthening the UK’s manufacturing capacity and capability. LSIMF define health resilience as the UK’s ability to withstand and recover from health emergencies such as pandemics, long-term healthcare challenges and supply chain disruption.“
Alex Leach, Deputy Director of Programmes

The Life Sciences Innovative Manufacturing Fund (LSIMF) is a capital grants fund which aims to build resilience for future health emergencies and capitalise on the UK’s world-leading research and development capabilities. The fund will enhance and accelerate affordable access to mature, new and emerging Life Sciences products for both pandemic and non-pandemic scenarios.

LSIMF will provide up to £520 million in capital grants for investment in the manufacture of human medicines and medical technology (including diagnostics, and MedTech products).

This is a new fund from previous UK Government Life Sciences manufacturing funds.

LSIMF is open to all eligible companies, including previous manufacturing grant recipients, as long as the application is for a different project.

Projects with a total cost (including capital expenditure) of at least £8 million are eligible to apply.

Closing date:  (Midnight)

Further information
Back